Note 3 - Balance Sheet Details

9 Months Ended

Sep. 30, 2024

3. Balance Sheet Details

Prepaid expenses and other current assets consisted of the following (in thousands):


	September 30,		December 31,
	2024		2023
Prepaid insurance	$	473	$	428
Other receivables		96		148
Prepaid subscriptions and fees		148		138
Prepaid software licenses		19		64
Deposits		12		—
Deferred equity issuance costs		76		112
Prepaid other		6		6
	$	830	$	896

Deferred equity issuance costs consist of the legal, accounting and other direct and incremental costs incurred by the Company related to its equity offerings, if not yet finalized as of the balance sheet date, or shelf registration statement. These costs will be netted against additional paid-in capital as a cost of the future equity issuances to which they relate. During the nine months ended September 30, 2024, the Company netted previously deferred equity issuance costs of approximately $37,000 against the additional paid-in capital recognized in conjunction with the warrant inducement transaction that closed on February 1, 2024 (see Note 5, Stockholders' Equity).

Other noncurrent assets consisted of the following (in thousands):


	September 30,		December 31,
	2024		2023
Prepaid insurance, less current portion	$	324	$	478
Other noncurrent assets		—		12
	$	324	$	490

Accrued liabilities consisted of the following (in thousands):


	September 30,		December 31,
	2024		2023
Accrued accounts payable	$	118	$	146
Accrued clinical trial expenses		174		20
Accrued CMC expenses		264		5
Accrued director stipends		59		106
Accrued severance and benefits (Note 9)		—		131
Accrued joint development expenses (Note 7)		669		98
Current portion of contingent consideration obligation (Note 4)		—		143
Accrued other		225		182
	$	1,509	$	831